Video1 Lab Act
-
Upload
alkaustariyah-lubis -
Category
Documents
-
view
223 -
download
0
Transcript of Video1 Lab Act
-
8/18/2019 Video1 Lab Act
1/20
Video #1
Rekam : Rabu, 9 – 10.30 wib (NO NGARET!!!!)
amea :
a" :
1. $oke : A%ka&. 'aak : *iddi+3. bu : A-a*/. Aak : odi. u"e: E2ia. 4a"ie u55u di %ua : "odi 6 2ia, 2eo 7 ke82a, a""ak*a 7 "e2a
ee #1
E2ia : (ma55i%) bu a-a (a di "oo a"ie 85 %a5i u55u)
A-a*iddi+aak : (ma"uk)
A%ka : e%ama a5i baak, ibu, "i%aka duduk.
A-a**iddi+ : ia5 dok, eima ka"i*
A%ka : ekea%ka ama "a8a a%ka, doke 8a5 "eda5 beu5a" di k%iik ii
E2ia : (5a"i* med eod) dok ii media% eod8a
A%ka : 8a maka"i* ("e8um :$) $e5a bu A-a* 31 a*u, 5uu ;A, dai
a%au baak8a de5a "iaa ama8a=
*iddi+ : *iddi+ dok
A%ka : eke
-
8/18/2019 Video1 Lab Act
2/20
A%ka : 8a5 ii aak kedua bu=
A-a* : i 8a5 eama dook, 8a5 kedua umu8a "au a*u.
A%ka : ma"i* dimaka i% kb8a bu=
A-a* : "uda* be*ei dok "emea%au ibu beabea idak mau u8a aak %a5i "a8a "aaka
-
8/18/2019 Video1 Lab Act
3/20
akai im%a "aami", u%a5 %eue 1&.0013.30 (NO NGARET!!, ka%au mau
dadai a""ak*a C amea :
a" :
1. $oke : 2eo&. uami: e2a3. "i : NV/. "i : a""ak*a (*8e*8oid). u"e : ida*. u"e : ke82a
-
8/18/2019 Video1 Lab Act
4/20
A%5oi*m memi%i* koa"e"i (ma"uki di 2ideo)
dika"i da koaidika"i
-
8/18/2019 Video1 Lab Act
5/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
Anemia halassemia 1 1 1 1 1 2
!ickle cell
disease
2 1 1 1 1 2
"ron#deficiency
anemia
1 1 1 1 1 2
$reast
disease
%amily history of
cancer
1 1 1 1 1 1
&urrent breast
cancer
4 4 4 4 4 1
$reast cancer in
past, no evidence
of disease for ' (
years
3 3 3 3 3 1
)ndiagnosedbreast mass
2 2 2 2 2 1
$enign breast
disease
1 1 1 1 1 1
&ervical &ervical 2 1 2 2 2 1
-
8/18/2019 Video1 Lab Act
6/20
-
8/18/2019 Video1 Lab Act
7/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
/riseofulvin
0/risactin
2 2 1 2 1 1
ifampin 0ifadin 3 3 2 3 1 1
All other
antibiotics
1 1 1 1 1 1
ndometrial cancer 1 1 1 1 4 4
ndometriosis 1 1 1 1 1 2
/allbladder
disease
Asymptomatic
gallstones
2 2 2 2 2 1
!ymptomatic
gallstones,
without
cholecystectomy
3 2 2 2 2 1
/allstones treated
with
cholecystectomy
2 2 2 2 2 1
regnancy#
related
2 1 1 1 1 1
-
8/18/2019 Video1 Lab Act
8/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
cholestasis in
past
+ormone#related
cholestasis in
past
3 2 2 2 2 1
+eadaches 5onmigrainous 1 1 1 1 1 1
Migrainous
ithout aura, age
6 3( years
2 1 2 2 2 1
ithout aura, age
7 3( years
3 1 2 2 2 1
ith aura, any
age
4 2 2 2 2 1
+"89A"*! +igh risk 1 1 1 1 2 2
+"8 infected 1 1 1 1 2 2
A"*! 0without 1 1 1 1 3 3
-
8/18/2019 Video1 Lab Act
9/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
drug interactions
+ypertension *uring prior
pregnancy, now
resolved
2 1 1 1 1 1
ell controlled 3 1 2 1 1 1
!ystolic $ 14-:
1(; mm +g ordiastolic $ ;-:
;; mm +g
3 1 2 1 1 1
!ystolic $ 71
-
8/18/2019 Video1 Lab Act
10/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
&irrhosis, severe 4 3 3 3 3 1
umors, benign 4 3 3 3 3 1
umors,
malignant
4 3 3 3 3 1
8iral hepatitis,
carrier
1 1 1 1 1 1
8iral hepatitis,
active
4 3 3 3 3 1
>besity $M" 7 3- kg per
m22 1 1 1 1 1
>varian cancer 1 1 1 1 3 3
>varian cysts and benign tumors 1 1 1 1 1 1
elvic
inflammatory
disease
ast, with
subse?uent
pregnancy
1 1 1 1 1 1
ast, without 1 1 1 1 2 2
-
8/18/2019 Video1 Lab Act
11/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
subse?uent
pregnancy
&urrent 1 1 1 1 4 4
ostabortion %irst trimester 1 1 1 1 1 1
!econd trimester 1 1 1 1 2 2
"mmediately after
septic abortion
1 1 1 1 4 4
ostpartum,
not
breastfeeding
6 2 days
postpartum
3 1 1 1 3 2
2 to 21 days 3 1 1 1 3 3
22 to 2@ days 1 1 1 1 3 3
' 2@ days 1 1 1 1 1 1
ostpartum,
breastfeeding
6 2 days
postpartum
4 3 3 3 3 2
-
8/18/2019 Video1 Lab Act
12/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
2 to 2 days 4 3 3 3 3 3
2@ to 41 days 4 3 3 3 1 1
< weeks to <
months
3 1 1 1 1 1
' < months 2 1 1 1 1 1
!eiBure
disorder
ithout drug
interactions
1 1 1 1 1 1
!eCually
transmitted
disease
8aginitis 1 1 1 1 2 2
+igh risk 1 1 1 1 3 3
&urrent purulent
cervicitis,
chlamydialinfection, or
gonorrhea
1 1 1 1 4 4
!moking Age 6 3( years 2 1 1 1 1 1
Age 7 3( years, 6 3 1 1 1 1 1
-
8/18/2019 Video1 Lab Act
13/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
1( cigarettes per
day
Age 7 3( years, 7
1( cigarettes per
day
4 1 1 1 1 1
!troke 4 2 3 2 2 1
!urgery Minor, withoutprolonged
immobiliBation
1 1 1 1 1 1
MaDor, without
prolonged
immobiliBation
2 1 1 1 1 1
MaDor, with
prolonged
immobiliBation
4 2 2 2 2 1
hyroid
disorders
!imple goiter,
hyperthyroidism,
hypothyroidism
1 1 1 1 1 1
)terine
fibroids
ithout distortion
of uterine cavity
1 1 1 1 1 1
-
8/18/2019 Video1 Lab Act
14/20
1 Method can be used without restriction.
2 Advantages of method generally outweigh risks.
3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.
4 Method not to be used.
Condition Qualifier for
condition
Combined
methods*
PROGESTIN-ONLY
PIL
L
INJECTIO
N
IMPLANT
† IUD
COPPER
IUD
ith distortion of
uterine cavity
1 1 1 1 4 4
8alvular heart
disease
)ncomplicated 2 1 1 1 1 1
&omplicated 4 1 1 1 2 2
8aricose veins 1 1 1 1 1 1
8enous
thrombosis
%amily history
0first#degree
relatives
2 1 1 1 1 1
!uperficial
thrombophlebitis
2 1 1 1 1 1
ast *89 4 2 2 2 2 1
&urrent *89 4 3 3 3 3 1
EFEstrogen/progestin pill, patch, or ring .
GFNot available in the United States.
-
8/18/2019 Video1 Lab Act
15/20
WH ! World Health rgani"ation# $U% ! intrauterine device# H$& ! human immunodeficienc' virus# ($%S !
ac)uired immunodeficienc' s'ndrome# + ! blood pressure# $ ! bod' mass inde-# %&. ! deep venous
thrombosis# +E ! pulmonar' embolism.
(dapted ith permission from edical Eligibilit' Criteria for Contraceptive Use0 1rd ed0 2eneva3 World Health
rgani"ation, 4556371, 7819:50 (ccessed %ecember 44, 455;, at3http3//0ho0int/reproductive<
health/publications/mec/mec0pdf .
#"ee & D ke"imu%a : *8oid di"ea"e bi"a ake 85 maa a'=
NV : "uda* dok, "a8a akai i% kombia"i
http://www.who.int/reproductive-health/publications/mec/mec.pdfhttp://www.who.int/reproductive-health/publications/mec/mec.pdfhttp://www.who.int/reproductive-health/publications/mec/mec.pdfhttp://www.who.int/reproductive-health/publications/mec/mec.pdf
-
8/18/2019 Video1 Lab Act
16/20
Veo : kaa be*ei da keaa 8a bu=
N2 : "ekia bu%a 85 %a%u, "a8a e8aa a%e5i dok
Veo : oo. A%e5i 8a, bu kaa eak*i ka%i me"=
NV : "a8a "uda* *ai ke i5a me" dok
Veo : wa*, ka%au mau a"a5 >' waku8a "uda* ea, aaka* ibu "uda*
meeuka mau me55uaka 85 maa=
NV : be%um dok, "a8a i5i me55uaka miii% ai aaka* %ebi* eeki
daiada @$ dok=
Veo : di media% eod ibu idak ada iwa8a e8aki bea da oea"i, bea
bu=
N2 : bea dok
Veo : uuk %ebi* eeki da e-"ie meuu "a8a baik8a ibu me55uaka @$
kaea eama adi ibu a%e5i, %a%u @$ e"ea"e kebe*a"i%a8a %ebi* i55i bu.@uk miii% "edii *au" diko"um"i "eia *ai da%am waku 8a5 "ama. Bika ibu
u8a ba8ak ke5iaa aku8a %ua da e82a : (ma"uk) ibu "i%aka ma"uk ke "ii.
N2 : (ke ua5a %ai bae5 ke82a)
Veo : "e%a' "ebe%um8a=
RiFki : be%um dok.
Veo : di "ii eu%i" ibu ekea *8o*8oid "eme
-
8/18/2019 Video1 Lab Act
17/20
RiFki : bea dok
Veo : koa"e"i aa ibu eak*i me"=
RiFki : "uda* "ekia dua mi55u 8a5 %a%u dok
Veo : eak*i be*ubu5a akai e5ama 5ak bu=
RiFki : ake 5ak 8a a=
e2a : e55ak dok
Veo : >a%au idak, ibu idak bi"a me55uaka >'8a "ekaa5, kia u55u dua
mi55u %a5i aaka* ai e" ke*ami%a8a o"ii aau idak. Tai ibu bi"a memi%i*
"ekaa5 a5a muda* ema"a5a8a ai
RiFki : ka%au ima iu a*a beaa %ama 8a dok=Veo : ima bi"a "amai 3 a*u.
e2a : iu a"a58a 5imaa 8a=
Veo : ai ada abu5 kei% m dia"a5 di%e5a aa" ibu8a, i"i8a *omoe
mee5a* ke*ami%a ak
e2a : 5imaa ma=
RiFki : "a8a mau im%a a
-
8/18/2019 Video1 Lab Act
18/20
-
8/18/2019 Video1 Lab Act
19/20
-
8/18/2019 Video1 Lab Act
20/20